News
Find all the latest news from Frontier Science Scotland below
choose a category:
COLONIZE | Annals of Internal Medicine
Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection
APHINITY | European Journal of Cancer
Body mass index and weight changes in patients with HER2-positive early
breast cancer: A sub-analysis of the APHINITY trial
Navigating the biopharma services landscape
BIO-Europe Spring 2025 Panel: ‘On-trend strategies: Navigating the biopharma services landscape’ On the first day of the BIO-Europe Spring event in Milan, BioXconomy’s Editor Millie Nelson hosted a lively panel on “Navigating the biopharma services landscape”....
ALEXANDRA | Journal of the American Medical Association (JAMA)
The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease.
ALTTO | ESMO Open
Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.
APHINITY | Journal of Clinical Oncology
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Keep CAALM and Carry On Doing Clinical Trials
Enabling excellence in clinical trial research services through collaborative working.
Frontier Science Scotland Strengthens Board of Trustees
Learn how Frontier Science Scotland’s flexible approach delivers exceptional results for clients in industry >>
Catalysing Excellence in Industry Trials
Learn how Frontier Science Scotland’s flexible approach delivers exceptional results for clients in industry >>
Ensuring exceptional service delivery for partners in academia
Discover how Frontier Science Scotland best serves clients in academia – featuring insights from Dr Shona Fielding, Head of Biostatistics >>
Spotlight on NordICC for Colorectal Cancer Awareness Month
For Colorectal Cancer Awareness Month, discover Frontier Science Scotland’s involvement in related studies, such as NordICC >>
Meet Dr Sarah Barry, Statistics Team Lead
Delve into Sarah’s impressive career. Discover what she likes about working at Frontier Science Scotland and her experience of being a woman in STEM >>
HERA
The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>
Why we give our employees two volunteering days each year
Discover the diverse projects our employees have been using their volunteering leave for
Our 15+ Years of Auditing NHS Scotland Research Projects
We’ve been providing auditing services to NHS Scotland since 2007. Read on to find out how we have contributed to improvements in Scottish hospital research sites…
How we’re building an inclusive, open culture around mental health
We work hard to create an inclusive, open culture around mental health at FSS. Find out the steps we’re taking this Mental Health Awareness Week (and year round)…
Supporting an academic clinical trials unit to meet study deadlines
How our biostatistics team was able to step in to seamlessly fill capacity gaps and ensure no study deadlines were missed.
OlympiA results in the subset of patients from Japan
The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.
How our data management experience and risk-based approach benefit clinical trial monitoring
Find out how our risk-based and flexible approach to monitoring helped deliver a complete and accurate database in a Norwegian clinical trial
Successfully Merging Two Databases Into One
How our flexibility, bespoke data review processes and collaborative approach led to outstanding and practice-changing results in a global breast cancer clinical trial
An Agile Approach to Statistical Analysis
How we developed an agile approach to statistical analyses for a clinical trial while the study protocol was still being amended
Cardiac Safety in the APHINITY trial
ESMO Open has published an article confirming the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.
An Interview with FSS Executive Director, Darren Gibson
Discover more about Darren, what he’s been focused on during the first 12 months in his new role and his plans for Frontier Science Scotland
NeoALTTO: European Journal of Cancer (EJC)
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Overall survival in the OlympiA trial
OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo
EPoS
The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...
NordICC
Learn how Frontier science scotland partnered with the University of Oslo for the nordicc study In collaboration with the University of Oslo, FSS held responsibility for trial data collection, management and cleaning processes. After inheriting the original Case...
FINESSE
Frontier Science has worked in partnership with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and in collaboration with Institut de Recherches Internationales SERVIER on the FINESSE trial. The trial was an open, 3-cohort, phase II...
ALEXANDRA
ALEXANDRA is a clinical trial partnership between Roche, the Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet (IJB) and Frontier Science. This is a phase 3, multicentre, randomised, open-label study comparing atezolizumab...
TOMORROW
Frontier Science collaborated with Janssen Actelion on the TOMORROW trial. The study assessed the efficacy, safety and pharmacokinetics of macitentan (Opsumit®) versus standard of care in children with pulmonary arterial hypertension (PAH). Frontier Science (Scotland)...
ALTTO & NEO-ALTTO
Frontier Science collaborated with the Breast International Group (BIG) on the ALTTO and Neo-ALTTO trials. These trials were built on the results from the successful HERA trial and aimed to study the benefit of adding Lapatinib to Herceptin® in both adjuvant and...
APHINITY
APHINITY is a large, randomised phase III, double-blind, placebo-controlled study that compares the efficacy and safety of chemotherapy plus trastuzumab and placebo with that of chemotherapy plus trastuzumab and pertuzumab as adjuvant therapy in approximately 4800...
OlympiA
OlympiA is a randomized, double-blind, parallel group, placebo-controlled multi-center phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary...
NoTOPain
NoTOPain was a randomised, crossover, placebo controlled, double-blind, Phase II study of cetuximab in patients with treatment-refractory, non-malignant severe chronic neuropathic pain. Neuropathic pain is a subtype of pain that can be caused by a variety of...
APHINITY | Annals of Oncology
Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up
OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology
Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
APHINITY | Journal of the National Cancer Institute (JNCI)
Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy
APHINITY | European Journal of Cancer (EJC)
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
APHINITY | AACR Cancer Research
Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.
The ALTTO Trial: Updated Results from the international phase III ALTTO trial (BIG2-06/Alliance N063D)
Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.
The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up
The JCO confirms the invasive disease-free survival benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early breast cancer.
A pooled analysis of the Cardiac Events in three adjuvant trials: HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials)
Breast Cancer Research and Treatment published that Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Further research is needed to individualize prevention and management of trastuzumab-associated cardiotoxicity.
The APHINITY Trial: Results of the Primary Analysis
An article published in the New England Journal of Medicine (NEJM) reports that pertuzumab, when added to chemotherapy and trastuzumab, significantly improved the rates of invasive-disease–free survival among patients with HER2-positive early breast cancer.
The HERA Trial: Final Analysis Results
An article published in The Lancet shares the results from the final analysis of the HERceptin Adjuvant (HERA) trial.
The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.
JAMA Internal Medicine reports on the investigation into participation rates, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries.
The ALTTO Trial: Results of the Primary Analysis
An article in the JCO reports that adjuvant treatment that includes lapatinib did not significantly improve Disease-Free Survival compared with trastuzmab alone and added toxicity. One year of adjuvant trastuzumab remains standard of care.
The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy
Findings from this study confirm that patients who achieve pathological complete response after neoadjuvant anti-HER2 therapy have longer event-free and overall survival than do patients without pathological complete response.
The HERA Trial: Cardiac Events at 8 years median follow-up
The JCO confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy.
The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer
An article in The Lancet reporting that dual inhibition of HER2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting.
The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification
An article in the JCO shows that the degree of HER2 amplification does not influence prognosis or benefit from adjuvant trastuzumab in patients treated with prior adjuvant chemotherapy.
The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups
The Annals of Oncology presents the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
The HERA Trial: Results of the First Planned Interim Analysis
An article in the New England Journal of Medicine reporting on the results of the first, planned interim analysis of the HERA Trial.